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RISPOR CODE OF ETHICS
PREAMBLE
ISPOR expects itself and its members to adhere to the highest ethical standards
because the Society recognizes that its activities and those of its members affect a
number of constituencies. These include but are not limited to:
‹ Patients who are ultimately going to experience the greatest impact of the
research.
Health care professionals who will be treating or not treating patients with
therapies, medications and procedures made available or not made available
because of the research.
‹ Decision-Makers and Payers who must decide what is covered so as to
optimize the health of the patient and resource utilization. This includes:
Œ Government Groups who require the results of research to set policy and
prices.
Œ Insurers who base health care coverage and/or payment decisions on the
research.
Œ Employers where the research affects their decisions on providing health
benefits.
Œ Administrators and Others such as U.S. managed care personnel who need
results that are both practical and useful.
Outcomes Researchers.
Pharmaceutical Manufacturers whose products are often the subject or focus
of the research.
Colleagues, where relationships in conducting research and related activities are
particularly critical.
Research employees concerned about how they are regarded, compensated
and treated by the researchers for whom they work
Students who work for researchers, where respect and lack of exploitation are
important. They are the future of the profession.
Clients for whom the research is conducted and the researchers’ relationships
with them.
he main objective of the Code is to help the science of pharmacoeconomics and
utcomes research avoid or otherwise deal with credibility challenges based on
ethods or bias concerns, through behaviors and practices intended to insure that
his research is designed, conducted, and reported in the most proper and ethical
ay possible. By accomplishing this, the various affected constituencies will be able
o trust and benefit from research findings as much as possible. The Code also
ncludes some general ethical considerations for the Society.
ESIGN AND RESEARCH PRACTICES
1. Members should maintain a current knowledge of research practices, with
due consideration of those practices most relevant to the research that is
being done in their own countries.
2. Members should adhere to the standards of practice for their respective
fields of research and identify any official Guidelines/Standards used.
3. Members’ research designs should be defined a priori, reported transpar-
ently, defended relative to alternatives, and planned to recognize and
minimize all types of bias.
4. Members should respect the rights of research subjects in designing and
conducting studies.
5. Members should respect the reputations and rights of colleagues when
engaged in collaborative projects.
6. Members should maintain and protect the integrity of the data used in their
studies.
7. Members should not draw conclusions beyond or inconsistent with what
their data would support.
SPONSORSHIP
8. Members should fully disclose the identity of sponsors of their research.
9. Members should strive to avoid bias and the appearance of bias in con-
ducting research, such as in the choice of methods and data inputs, or in
the selective reporting of results.
10. Members should be aware of conflicts of interest and the appearance of
conflicts of interest. As a point of reference, members should look to the
rules on disclosure of interest laid down by major peer reviewed journals.11. Members should maintain their professional autonomy and objectivity in
conducting and reporting, in writing or verbally, research findings.
UBLICATION AND DISSEMINATION
12. Members should endeavor to publicly disseminate their work, and to
publish it in peer reviewed journals when possible.
13. Members should discourage, where possible, listing of an author on any
publication where the individual has not performed substantial work. As a
point of reference, members should look to the checklists provided by
major peer reviewed journals to assist them in deciding inclusion of au-
thors.
14. Members should seek to establish, in advance, a clear agreement on
whether the results of a given piece of work could be published. This could
include statements on whether the sponsor has a right to review or
approve any manuscript prior to publication. Considerations could include
revelations of safety issues.
15. Members should respect contractual rights when they agree to perform
work for hire and should refrain from disseminating information which they
agreed in advance to keep proprietary.
16. Methods sections of papers should give thorough, transparent attention to
all measures taken to minimize bias.
17. Methods sections of papers should identify and justify all departures from
the a priori analysis plan.
18. Members should work with editors of journals and other publications to
encourage the establishment and/or maintenance of an appropriate peer
review process that examines the quality of the methodological rigor
independently of the institution for which the individual works.
19. Any contributor to a report or publication should disclose any current or
past relationships with a company or competitor of any product discussed
in the work.
ELATIONSHIPS WITH OTHERS
20. Members should treat their research employees with respect and should
compensate them fairly for their work.
21. Members should protect and promote the interests of their employers,
provide competent work, adhering to these broader guidelines, and pro-
tect proprietary information.
22. Members should treat students with respect and refrain from exploiting
them under any circumstances.
23. Members should provide competent, honest and objective work for clients,
adhering at all times to relevant standards of conduct for conducting and
reporting research.
OLE OF ISPOR
24. ISPOR should publicize this Code of Ethics to members and non-members
involved in pharmacoeconomics and outcomes research.
25. ISPOR should strive for a balance in sponsorship of its conferences and
other activities, thereby avoiding the appearance of bias or conflict of
interest.
26. Because, as a practical matter, most funding will come from commercial
interests, ISPOR should continue to maintain its own statement of objec-
tivity and autonomy from sponsors.
27. ISPOR should strive to assure that its journal, Value in Health, only pub-
lishes papers that have gone through a rigorous peer- review process.
28. As much as is possible, ISPOR should have a Board of Directors that is
representative of the various constituencies the Society serves.
29. Similarly, to the extent that it is feasible, the ISPOR program planning and
selection committees should have membership representative of all of its
major constituencies.
30. Like other professional societies, ISPOR should be conscious of broader
ethical issues impacting on global and regional medical resource alloca-
tion, public health policies and the global healthcare environment. These
issues include but are not limited to: prejudice, equity in healthcare delivery
and access. ISPOR should encourage researchers to utilize opportunities in
their activities and work to address these issues.
